Regulated information
- 06 September 2010 - Paris (France)
Total number of voting rights and total number of shares
- 03 September 2010 - Liestal (Switzerland) and Paris (France)
Santhera and Ipsen Enter into Licensing Agreement Santhera and Ipsen Enter into Licensing Agreement in Parkinson’s Disease
- 31 August 2010 - Paris (France)
Ipsen’s Half-year 2010 Results
- 31 August 2010 - Paris (France)
Half Year Financial Report
- 03 August 2010 - Paris (France)
Outstanding shares and voting rights
- 05 July 2010 - Paris (France)
Outstanding shares and voting rights
- 05 July 2010 - Paris (France)
Half-year statement of Ipsen’s liquidity contract
- 26 June 2010 - Paris (France)
Ipsen’s partner Roche confirms the promising efficacy profile of Taspoglutide
- 22 June 2010 - Paris (France)
Encouraging results of GuidAge®, large scale European trial conducted in the prevention of Alzheimer’s Dementia
- 18 June 2010 - Paris (France)
Ipsen’s partner Roche announces amendment of the trial protocols for the taspoglutide phase III programme
First Half 2010 Results presentation
2009 Ipsen Annual Report
CONTACT US
Investor Relations
Tel.: +33 (0)1 58 33 51 29
Fax: +33 (0)1 58 33 50 63
Send an e-mail